Ayfer BAKIR, Sema ALACAM, Mustafa GÜNEY, Mehmet Tevfik YAVUZ

Investigation of herpes simplex virus type 2 seroprevalence in all age groups

Aim: Herpes simplex virus type 2 (HSV-2) is one of the most common causes of sexually transmitted genital infections and remains latent in neuronal cells for the lifetime of humans. This retrospective study aimed to determine the seroprevalence of HSV-2 and evaluate its relationship with age and gender. Materials and Methods: In this study, 976 serum samples sent to Virology Laboratory between October 2016 and December 2018 were evaluated. HSV-2 IgM and IgG antibodies were tested with VirClia EIA/CLIA device by using a commercial kit. Results: The median age of 976 patients included in the study was 31 (0−88). Fortythree point three percent (423) of the patients were male. HSV-2 IgM was found in 0.3% (3/976) of the patients and HSV-2 IgG was found in 3.7% (36/976). HSV-2 IgG was detected in 2.8% of male patients (12/423) and 4.3% (24/553) of female patients (p = 0.120). The highest HSV-2 IgG seropositivity rate was between the ages of 40 and 59 in both genders (8.3% in males and 8.3% in females) (p = 0.010 and p = 0.250 respectively). Conclusion: The HSV-2 IgG seropositivity rates we detected in this study were consistent with other study data in our country and in the world. Studies on HSV-2 IgG seroprevalence and determination of the age groups at risk will be guides for public health studies aimed for protection against HSV-2 infection.

PDF

___

1. ICTV. 9th Report (2011). Virus Taxonomy: 2018b Release. Herpesviridae.
2. Mathew Jr J, Sapra A. Herpes Simplex Type 2. [Updated 2021 Feb 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
3. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Postgrad Med J 2008;84:299-306.
4. Sexually Transmitted Infections Treatment Guidelines, 2021. Available from: https: //www.cdc.gov/std/treatmentguidelines/herpes.htm accessed on August, 2021.
5. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-73.
6. Schiffer JT, Corey L. New concepts in understanding genital herpes. Curr Infect Dis Rep 2009;11:457-64.
7. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008;198:1141-9.
8. Pieknik JR, Bertke AS, Krause PR. Herpes Simplex Virus 2 in Autonomic Ganglia: Evidence for Spontaneous Reactivation. J Virol 2019;93:e00227-19.
9. Johnston C, Corey L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev 2016;29:149-61.
10. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
11. Delany-Moretlwe S, Jentsch U, Weiss H, et al. Comparison of focus Herpes Select and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sex Transm Infect 2010;86:46-50.
12. Cunningham AL, Taylor R, Taylor J, et al. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sex Transm Infect 2006;82:164-8.
13. James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ 2020;98:315-29.
14. Sierra CA, Bedoya AM, Paris S, et al. Prevalence of specific herpes simplex virus-2 antibodies and associated factors in women of a rural town of Colombia. Trans R Soc Trop Med Hyg 2011;105:232-8.
15. Auvert B, Ballard R, Campbell C, et al. HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS 2001;15:885-98.
16. Uribe-Salas F, Hernández-Avila M, Juárez-Figueroa L, et al. Risk factors for herpes simplex virus type 2 infection among female commercial sex workers in Mexico City. Int J STD AIDS 1999;10:105-11.
17. Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Heineman TC, Dubin G, Belshe RB. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013;56:344- 51.
18. Chemaitelly H, Nagelkerke N, Omori R, Abu-Raddad LJ. Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. PLoS One 2019;14:e0214151.
19. Looker KJ, Magaret AS, May MT, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PloS One 2015;10:e0140765.
20. Ozdemir M, Kalem F, Feyzioglu B, Baysal B. Investigation of Viral Pathogen During Pregnancy in a City Region in Turkey. Anatol J Clin Investig 2011;5:78-81.
21. Ozdemir R, Er H, Baran N, et al. HSV-1 and HSV-2 seropositivity rate in pregnant women admitted to Izmir Ataturk Research and Training Hospital, Turkey. Mikrobiyol Bul 2009;43:709-11.
22. Topbaş M, Çan E, Kaklıkkaya N, et al. Herpes simplex virus type-2 seroprevalence among adults aged 20-49 in Trabzon. Nobel Med 2012;8:85-90.
23. Maral I, Biri A, Korucuoğlu U, et al. Seroprevalences of herpes simplex virus type 2 and Chlamydia trachomatis in Turkey. Arch Gynecol Obstet 2009;280:739-43.
24. Arseven G, Tuncel E, Tuncel S, et al. Distribution of HSV1 and HSV 2 antibodies in pregnant women. Mikrobiyol Bul 1992;26:359-66.
25. Cengiz SA, Cengiz L, Us E, Cengiz AT. Gebe Kadınlarda Herpes simplex Virus Tip-1 ve 2, IgG ve IgM Antikorlarının, ELISA ile Araştırılması. İnönü Üniversitesi Tıp Fakültesi Dergisi 2004;11;227-31.
26. Dolar N, Serdaroglu S, Yilmaz G, Ergin S. Seroprevalence of herpes simplex virus type 1 and type 2 in Turkey. J Eur Acad Dermatol Venereol 2006;20:1232-6.
27. Duran N, Yarkin F, Evruke C, Koksal F. Asymptomatic herpes simplex virus type 2 (HSV-2) infection among pregnant women in Turkey. Indian J Med Res 2004;120:106-10.
28. Rodríguez AC, Castle PE, Smith JS, et al. A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Sex Transm Infect 2003;79:460-5.
29. Uddin Moyen PKM, Morshed AMA, Fatema K, et al. Prevalence of Herpes Simplex Virus Infection among Adults Citizens of Dhaka. Blood Disord Transfus 2015;S5:1.
30. Sauerbrei A, Schmitt S, Scheper T, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. Euro Surveillance 2011;3;16.
31. Shen JH, Huang KY, Chao-Yu C, et al.Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007. PLoS One 2015;10:e0134178.
32. Baker DA, Pressley A, Meek L, et al. HSV serologic testing for pregnant women:willingness to be tested and factors affecting testing. Infect Dis ObstetGynecol2011:874820.
33. Stankiewicz Karita HC, Moss NJ, Laschansky E, et al. Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy. Open Forum Infect Dis 2017;4:ofx248.
34. Domercant JW, Jean Louis F, Hulland E, et al. Seroprevalence of Herpes Simplex Virus type-2 (HSV-2) among pregnant women who participated in a national HIV surveillance activity in Haiti. BMC Infect Dis 2017;17:577.
35. Woestenberg PJ, Tjhie JH, de Melker HE, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis 2016;16:364.
36. Rezaei-Chaparpordi S, Assmar M, Amirmozafari N, et al. Seroepidemiology of herpes simplex virus type 1 and 2 in northern iran. Iran J Public Health 2012;41:75-9.